- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07441694
Étude de l'INCA036978 chez les participants atteints de néoplasmes myéloprolifératifs
Une étude de phase 1, ouverte, multicentrique de l'INCA036978 chez des participants atteints de néoplasmes myéloprolifératifs
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Incyte Corporation Call Center (US)
- Numéro de téléphone: 1.855.463.3463
- E-mail: medinfo@incyte.com
Sauvegarde des contacts de l'étude
- Nom: Incyte Corporation Call Center (ex-US)
- Numéro de téléphone: +800 00027423
- E-mail: eumedinfo@incyte.com
Lieux d'étude
-
-
-
Aachen, Allemagne, D-52074
- Recrutement
- University Medical Center Rwth Aachen
-
Berlin, Allemagne, 10117
- Recrutement
- Charite Universitaetsmedizin Berlin - Campus Charite Mitte
-
Freiburg im Breisgau, Allemagne, 79106
- Recrutement
- Universitatklinikum Freiburg
-
Halle, Allemagne, 06120
- Recrutement
- Universitatsklinikum Halle (Saale)
-
Mainz, Allemagne, 55131
- Pas encore de recrutement
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
-
-
-
New South Wales
-
Concord, New South Wales, Australie, 02139
- Recrutement
- Concord General Repatriation Hospital
-
St Leonards, New South Wales, Australie, 02065
- Recrutement
- Royal North Shore Hospital
-
-
Queensland
-
Auchenflower, Queensland, Australie, 04066
- Recrutement
- Icon Cancer Centre
-
-
Victoria
-
East Melbourne, Victoria, Australie, 03002
- Recrutement
- Epworth Health Care
-
-
Western Australia
-
Nedlands, Western Australia, Australie, 06009
- Recrutement
- Linear Clinical Research
-
-
-
-
-
Liège, Belgique, 04000
- Pas encore de recrutement
- Centre Hospitalier Universitaire (Chu) de Liege
-
Roeselare, Belgique, 08800
- Pas encore de recrutement
- AZ DELTA
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recrutement
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Pas encore de recrutement
- McGill University Jewish General Hospital
-
-
-
-
-
Jongno-gu, Seoul, Corée du Sud, 03080
- Pas encore de recrutement
- Seoul National University Hospital
-
Seocho-gu, Seoul, Corée du Sud, 06591
- Pas encore de recrutement
- The Catholic University of Korea Seoul St. Mary'S Hospital
-
-
-
-
-
Badalona, Espagne, 08916
- Pas encore de recrutement
- Hospital Universitari Germans Trias I Pujol
-
Las Palmas de Gran Canaria, Espagne, 35010
- Pas encore de recrutement
- Hospital Universitario de Gran Canaria Dr. Negrin
-
Madrid, Espagne, 28041
- Pas encore de recrutement
- Hospital Universitario 12 de Octubre
-
-
-
-
-
Bordeaux, France, 33076
- Recrutement
- Francois-Xavier
-
Paris, France, 75010
- Recrutement
- Hospital Saint Louis
-
Villejuif, France, 94805
- Recrutement
- Institut Gustave Roussy
-
-
-
-
-
Bologna, Italie, 40138
- Pas encore de recrutement
- Aou Policlinico S. Orsola-Malpighi
-
Milan, Italie, 20122
- Pas encore de recrutement
- Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
-
Roma, Italie, 00168
- Pas encore de recrutement
- A. Gemelli University Hospital, Catholic University of the Sacred Heart
-
Udine, Italie, 33100
- Pas encore de recrutement
- Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
-
-
-
-
-
Kashiwa Chiba, Japon, 277-0882
- Pas encore de recrutement
- National Cancer Center Hospital East
-
Toon, Ehime, Japon, 791-0204
- Pas encore de recrutement
- Ehime University Hospital
-
-
-
-
-
London, Royaume-Uni, SE1 9RT
- Pas encore de recrutement
- Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
-
Nottingham, Royaume-Uni, NG5 1PB
- Pas encore de recrutement
- Nottingham University Hospitals
-
Oxford, Royaume-Uni, OX3 7LE
- Recrutement
- University of Oxford
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Pas encore de recrutement
- University of Alabama At Birmingham
-
-
California
-
Irvine, California, États-Unis, 92618
- Recrutement
- City of Hope-Lennar Foundation Cancer Center
-
Los Angeles, California, États-Unis, 90095
- Pas encore de recrutement
- UCLA Medical Hematology & Oncology
-
Los Angeles, California, États-Unis, 90033
- Pas encore de recrutement
- Usc Norris Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Pas encore de recrutement
- Yale Cancer Center
-
-
Florida
-
Miami, Florida, États-Unis, 33136
- Pas encore de recrutement
- University of Miami
-
Tampa, Florida, États-Unis, 33612
- Pas encore de recrutement
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Winship Cancer Institute of Emory University
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Pas encore de recrutement
- John Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Massachusetts General Hospital
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63108
- Pas encore de recrutement
- Washington University School of Medicine
-
-
New York
-
New York, New York, États-Unis, 10065
- Pas encore de recrutement
- Weill Cornell Medicine
-
New York, New York, États-Unis, 10029
- Pas encore de recrutement
- Mount Sinai School of Medicine
-
New York, New York, États-Unis, 10021
- Pas encore de recrutement
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- Recrutement
- University of North Carolina At Chapel Hill
-
Charlotte, North Carolina, États-Unis, 28204
- Pas encore de recrutement
- Levine Cancer Institute
-
Durham, North Carolina, États-Unis, 27705
- Pas encore de recrutement
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Pas encore de recrutement
- Cleveland Clinic
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- Ohio State University
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Tristar Bmt/Tcto
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Pas encore de recrutement
- University of Texas M. D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Pas encore de recrutement
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Pas encore de recrutement
- Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Life expectancy > 6 months.
- Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease).
- Participants with MF, PV and ET as defined in the protocol.
Exclusion Criteria:
- Presence of any hematological malignancy other than MF, PV, or ET.
- Malignancy within the last 3 years prior to enrollment.
- Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection.
- Clinically significant or uncontrolled cardiac disease.
- Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months.
- Laboratory values outside the Protocol-defined ranges.
- Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment.
- Presence of chronic or current active infectious disease requiring systemic treatment.
- Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug.
- Prior radiation therapy within 28 days before the first dose of study treatment.
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1a: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen as monotherapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. |
|
Expérimental: Part 1b: Dose Escalation
INCA036978 will be administered at a protocol defined starting regimen in combination with a standard disease-directed therapy to identify the MTD and/or RDE(s). |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
|
Expérimental: Part 2a: Dose Expansion
INCA036978 will be administered as monotherapy at the RDE(s) identified during Part 1 |
INCA036978 will be administered at protocol defined dose. |
|
Expérimental: Part 2b: Dose Expansion
INCA036978 will be administered in combination with a standard disease-directed therapy at the RDE(s) identified during Part 1. |
INCA036978 will be administered at protocol defined dose. A standard disease-directed therapy will be administered according to Prescribing Information/SmPC. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with Dose Limiting Toxicities (DLT)s in Part 1
Délai: Up to 28 days
|
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol. |
Up to 28 days
|
|
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Délai: Up to approximately 2 years
|
Defined as adverse events AE (either reported for the first time or the worsening of a pre-existing event) occurring after the first dose of study drug and up to 60 days after last dose of study drug or until the start of a new disease-directed therapy, whichever occurs first. |
Up to approximately 2 years
|
|
Number of participants with TEAEs leading to dose modification or discontinuation
Délai: Up to approximately 2 years
|
Number of participants with TEAEs leading to study drug modifications (interruptions, dose reduction) or discontinuation. |
Up to approximately 2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pharmacokinetics Parameter: Cmax of INCA036978
Délai: Up to approximately 2 years
|
Defined as maximum observed plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Tmax of INCA036978
Délai: Up to approximately 2 years
|
Defined as the time to reach the maximum plasma concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmax,ss of INCA036978
Délai: Up to approximately 2 years
|
Defined as the maximum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Cmin,ss of INCA036978
Délai: Up to approximately 2 years
|
Defined as the minimum observed plasma concentration at steady state of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC(0-t) of INCA036978
Délai: Up to approximately 2 years
|
Defined as the area under the concentration-time curve up to the last measurable concentration of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: AUC 0-∞ of INCA036978
Délai: Up to approximately 2 years
|
Defined as the area under the concentration-time curve from 0 to infinity of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: CL/F of INCA036978
Délai: Up to approximately 2 years
|
Defined as the apparent clearance of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: Vz/F of INCA036978
Délai: Up to approximately 2 years
|
Defined as the apparent volume of distribution of INCA036978. |
Up to approximately 2 years
|
|
Pharmacokinetics Parameter: t1/2 of INCA036978
Délai: Up to approximately 2 years
|
Defined as the apparent terminal phase disposition half-life of INCA036978. |
Up to approximately 2 years
|
|
For participants with myelofibrosis (MF): Percentage of participants achieving spleen volume reduction as defined in the protocol
Délai: Week 12 and Week 24
|
Defined as percentage of participants with a protocol defined spleen volume reduction. |
Week 12 and Week 24
|
|
For participants with MF and anemia: Anemia Response as defined in the protocol
Délai: Up to approximately 2 years
|
For non transfusion-dependent (TD) participants: An Hb increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol. |
Up to approximately 2 years
|
|
For participants with polycythemia vera (PV): Peripheral blood count remission as defined by the protocol.
Délai: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
|
For participants with essential thrombocythemia (ET): Peripheral blood count remission as defined by the protocol.
Délai: Up to approximately 2 years
|
Peripheral blood count remission as defined by the protocol. |
Up to approximately 2 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Incyte Medical Monitor, Incyte Corporation
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies hématologiques
- Troubles de la coagulation sanguine
- Maladies de la moelle osseuse
- Troubles hémorragiques
- Troubles des plaquettes sanguines
- Tumeurs de la moelle osseuse
- Tumeurs hématologiques
- Maladies hémiques et lymphatiques
- Thrombocytose
- Troubles myéloprolifératifs
- Thrombocytémie essentielle
- Polyglobulie Vera
- Myélofibrose primaire
Autres numéros d'identification d'étude
- INCA036978-101
- 2026-525217-31-00 (Identificateur de registre: EU CT Number)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .